Search for Clinical Trial Results
Ascites - 164 Studies Found
Status | Study |
Completed |
Study Name: Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites Condition: Refractory Malignant Ascites Date: 2013-05-08 Interventions: Drug: bevacizumab Other Name: Avastin |
Completed |
Study Name: A Feasibility Study of the Automated Fluid Shunt (AFS) for Automated Ascites Removal Condition: Refractory Ascites Date: 2009-03-25 Interventions: Device: AFS System AFS System with patient specific flow rate |
Terminated |
Study Name: Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites Condition: Malignant Ascites Date: 2015-07-01 Interventions: Drug: Intraperitoneal Bevacizumab Bevacizumab 200mg diluted in 250 ml of normal saline |
Completed |
Study Name: Study of Efficacy of a Vasopressin 2 Receptor Antagonist M0002 for Treatment of Ascites in Cirrhotic Subjects With Hypo- or Normonatraemia Condition: Cirrhotic Ascites Date: 2010-08-10 Interventions:
|
Completed |
Study Name: Impact Of Timing Of Drainage Of Massive Ascites On Operative And Post-Operative Course In Living-Donor Liver Transplant Recipients. A Prospective Randomized Controlled Trial. Condition: Massive Ascites Date: 2016-08-11 Interventions:
|
Completed |
Study Name: Retrospective Analysis of Patients Treated With Bevacizumab in GHPSJ Intraperitoneal for the Treatment of Refractory Malignant Ascites Condition: Refractory Malignant Ascites Date: 2016-09-01 Interventions: Other: No intervention. Descriptive study |
Completed |
Study Name: Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites Condition:
Date: 2007-07-13 Interventions: Drug: satavaptan (SR121463B) |
Completed |
Study Name: Satavaptan Dose-Ranging Study in the Prevention of Ascites Condition:
Date: 2007-07-13 Interventions: Drug: satavaptan (SR121463B) |
Completed |
Study Name: ALFApump System Versus Standard of Care in Ascites Treatment Condition: Refractory or Recurrent Ascites Date: 2012-01-31 Interventions:
|
Completed |
Study Name: Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites Condition: Malignant Ascites Due to Epithelial Carcinoma Date: 2010-01-13 Interventions: Drug: catumaxomab 4 intraperitoneal infusions within 11 days administered over 3 hours via an indwelling |